Heart Failure Clinical Trial
Official title:
Clinical Translational Research of Novel Wearable Device Based on Patented Sensing Technology in Non-Invasive Management of Heart Failure
Heart failure (HF) is a major cardiovascular disease with high readmission and mortality rate. A wearable device that could remotely monitor and detect the worsening HF early before the symptoms appear will help reduce HF readmissions effectively. The purpose of the current study is to examine the efficiency of a novel wearable device based on flexible strain sensor comparing to the clinical 'gold standard,' and then transform it into a clinical application.
Status | Not yet recruiting |
Enrollment | 108 |
Est. completion date | April 30, 2025 |
Est. primary completion date | April 30, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Diagnosis of HF = 3 months 2. Diagnosis of NYHA Class III HF 3. Subjects with age = 18 years 4. At least 1 HF hospitalization within 12 months prior to enrollment 5. Subjects with elevated ambulatory levels of BNP/NT-proBNP Exclusion Criteria: 1. Subjects unable to cooperate to complete the trial. 2. Subjects with severe arrhythmia. 3. Subjects with cardiac shock. 4. Subjects with acute myocardial infarction. 5. Subjects with local skin infections and injuries in the jugular vein area 6. Subjects with active uncontrolled infections 7. Subjects with eGFR < 25 mL/min/1.73m2 8. Pregnant women, or women likely to undergo pregnancy 9. Subjects with life expectancy less than 6 months |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
China-Japan Friendship Hospital |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Subjects Included the Endpoint of Cardiovascular Mortality | Rate of cardiovascular mortality will be monitored via follow-up. | Up to 6 months | |
Other | Subjects Included the Endpoint of all-cause Mortality | Rate of all-cause mortality will be monitored via follow-up. | Up to 6 months | |
Primary | Rate of Hospital Readmissions for Heart Failure | Total hospitalizations for heart failure will be monitored via follow-up. | Up to 6 months | |
Secondary | Concordance of the Jugular Vein Pressure with the RHC Measurement | Accuracy of jugular vein pressure measurements by the novel wearable device compared to right heart catheterization. | Up to 6 months | |
Secondary | Change From Baseline N-terminal Pro-brain Natriuretic Peptide(NT-proBNP) or Brain Natriuretic Peptide(BNP) | Change from baseline to 6 months in N-terminal pro-brain natriuretic peptide (NT-proBNP) or Brain Natriuretic Peptide(BNP). NT-proBNP/BNP level will be measured using commercial kits system during the follow-up period. Change from baseline was defined as the value of NT-proBNP/BNP at 6 months minus the baseline value. Baseline value was defined as the mean of all available measurements from the screening visit. | Up to 6 months | |
Secondary | Change in Exercise Capacity as Measured by the 6-Minutes-Walking-Test (6MWT) Distance. | Change from baseline to 6 months in exercise capacity as measured by the distance walked in 6 minutes in standardised conditions. | Up to 6 months | |
Secondary | Compliance Percentage of Patients | Patient adherence to daily measurement and transmission of sensor readings will be recorded. | Up to 6 months | |
Secondary | Change in Quality of Life | Quality of life will be measured with the Kansas City Cardiomyopathy Questionnaire (KCCQ) answered by the patients directly on a patient application.KCCQ is a 23-item, self-administered instrument that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge, and quality of life. The KCCQ total symptom score incorporates the symptom domains into a single score. Scores are transformed to a range of 0-100, in which higher scores reflect better health status. | Up to 6 months | |
Secondary | Change in New York Heart Association (NYHA) functional class. | NYHA class will be evaluated according to the patients' clinical characteristics during the follow-up.NYHA Functional Classification places patients in one of four categories based on how much they are limited during physical activity; Class I being best and Class IV being the worst functional class. Class I has no limitation to physical activity, Class II has slight limitation to physical activity, Class III has marked limitation of physical activity, and Class IV is unable to carry out any physical activity without severe discomfort. | Up to 6 months | |
Secondary | Freedom From a Device/System-related Complication | Device/System-related Complications refer to adverse events such as device failure and allergy. | Up to 6 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05654272 -
Development of CIRC Technologies
|
||
Recruiting |
NCT05650307 -
CV Imaging of Metabolic Interventions
|
||
Recruiting |
NCT05196659 -
Collaborative Quality Improvement (C-QIP) Study
|
N/A | |
Active, not recruiting |
NCT05896904 -
Clinical Comparison of Patients With Transthyretin Cardiac Amyloidosis and Patients With Heart Failure With Reduced Ejection Fraction
|
N/A | |
Completed |
NCT05077293 -
Building Electronic Tools To Enhance and Reinforce Cardiovascular Recommendations - Heart Failure
|
||
Recruiting |
NCT05631275 -
The Role of Bioimpedance Analysis in Patients With Chronic Heart Failure and Systolic Ventricular Dysfunction
|
||
Enrolling by invitation |
NCT05564572 -
Randomized Implementation of Routine Patient-Reported Health Status Assessment Among Heart Failure Patients in Stanford Cardiology
|
N/A | |
Enrolling by invitation |
NCT05009706 -
Self-care in Older Frail Persons With Heart Failure Intervention
|
N/A | |
Recruiting |
NCT04177199 -
What is the Workload Burden Associated With Using the Triage HF+ Care Pathway?
|
||
Terminated |
NCT03615469 -
Building Strength Through Rehabilitation for Heart Failure Patients (BISTRO-STUDY)
|
N/A | |
Recruiting |
NCT06340048 -
Epicardial Injection of hiPSC-CMs to Treat Severe Chronic Ischemic Heart Failure
|
Phase 1/Phase 2 | |
Recruiting |
NCT05679713 -
Next-generation, Integrative, and Personalized Risk Assessment to Prevent Recurrent Heart Failure Events: the ORACLE Study
|
||
Completed |
NCT04254328 -
The Effectiveness of Nintendo Wii Fit and Inspiratory Muscle Training in Older Patients With Heart Failure
|
N/A | |
Completed |
NCT03549169 -
Decision Making for the Management the Symptoms in Adults of Heart Failure
|
N/A | |
Recruiting |
NCT05572814 -
Transform: Teaching, Technology, and Teams
|
N/A | |
Enrolling by invitation |
NCT05538611 -
Effect Evaluation of Chain Quality Control Management on Patients With Heart Failure
|
||
Recruiting |
NCT04262830 -
Cancer Therapy Effects on the Heart
|
||
Completed |
NCT06026683 -
Conduction System Stimulation to Avoid Left Ventricle Dysfunction
|
N/A | |
Withdrawn |
NCT03091998 -
Subcu Administration of CD-NP in Heart Failure Patients With Left Ventricular Assist Device Support
|
Phase 1 | |
Recruiting |
NCT05564689 -
Absolute Coronary Flow in Patients With Heart Failure With Reduced Ejection Fraction and Left Bundle Branch Block With Cardiac Resynchronization Therapy
|